Holen Sie sich die Stockscreener-App
29.49
2.16%
-0.65
Vorhandelsmarkt:
29.49
Amylyx Pharmaceuticals Inc Aktie (AMLX) Neueste Nachrichten
Amylyx Pharmaceuticals, Inc. (AMLX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Amylyx Pharmaceuticals, Inc. (AMLX) stock price, news, quote and history - Yahoo Finance Singapore
Amylyx Pharmaceuticals (AMLX) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum - BioSpace
Amylyx Pharmaceuticals Stock Price Forecast. Should You Buy AMLX? - StockInvest.us
Amylyx Pharmaceuticals, Inc. (AMLX) Stock Analysis: Tapping into a 24.82% Upside Potential - DirectorsTalk Interviews
Amylyx Pharmaceuticals (AMLX) Signs Avexitide Supply Deals, Is The Stock Fully Priced? - simplywall.st
Amylyx (AMLX) Rallies +3.86% as Bulls Target $35.58 2026-09-17Sell Signal Alerts - careplusvn.com
Have Amylyx Pharmaceuticals Insiders Been Selling Stock? - webull.com
AMLX: Avexitide achieved strong efficacy in PBH, with NDA filing and launch preparations underway - TradingView
AMLX: Avexitide achieved robust efficacy in PBH, with NDA filing and commercial launch targeted for 2027 - tradingview.com
Amylyx (AMLX) CMO auto-sells 10,028 shares for taxes - stocktitan.net
Automatic tax sale by Amylyx (NASDAQ: AMLX) CFO - Stock Titan
Amylyx (NASDAQ: AMLX) co-CEO sells shares to cover taxes - Stock Titan
Amylyx Pharmaceuticals (AMLX) co-CEO sells shares to cover tax bill - Stock Titan
Automatic tax-share sale by Amylyx (AMLX) legal chief - Stock Titan
Amylyx Pharmaceuticals Insiders Sold Shares Worth Over $1.9M - TradingView
Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More InformationAMLX - ACCESS Newswire
Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your RightsAMLX - ACCESS Newswire
Amylyx Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Automatic stock sale for taxes ahead at Amylyx Pharmaceuticals (AMLX) - Stock Titan
Amylyx (NASDAQ: AMLX) insider schedules automatic 60K-share sale - Stock Titan
Amylyx (NASDAQ: AMLX) officer lines up tax-driven share sale - Stock Titan
Amylyx (AMLX) insider schedules automatic tax share sale - Stock Titan
Automatic Amylyx (AMLX) stock sale set to cover taxes - Stock Titan
After two decades at Alkermes, a biotech CFO joins Tortugas’ board - Stock Titan
Amylyx Pharmaceuticals Inks Avexitide Supply Deals With Bachem and Polypeptide; $30 Million Upfront to Reserve Capacity - TradingView
Amylyx Pharmaceuticals | 8-K: Current report - Moomoo
Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference - Business Wire
The Manufacturers Life Insurance Company Makes New $679,000 Investment in Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat
Amylyx Pharmaceuticals (AMLX) director exercises 50K stock options - Stock Titan
Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%? - Yahoo Finance
Amylyx Pharmaceuticals (AMLX) Is Down 10.1% After Strong Phase 3 Avexitide Data And $500M Equity Raise – Has The Bull Case Changed? - webull.com
Should Eli Lilly Investors Be Worried About a Threat From Amylyx? - Yahoo Finance
Oracle Stock Stands Out Among Healthy High Growth Potential Picks - sahmcapital.com
Oracle Stock And Palantir Shares Stand Out For High Growth Investors - Sahm
Guggenheim Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Raises Target Price to $57 - Moomoo
Guggenheim raises Amylyx stock price target on financing, trial data By Investing.com - Investing.com Australia
Oracle Stock And Two Other Growth Names With Stronger Balance Sheet Appeal - sahmcapital.com
Amylyx (AMLX) Quarter in Focus: EPS Misses Its Estimate in the Available Record; Price Move: Shares Move 2.52% Lower in the Latest ReadingRetail Earnings Report - careplusvn.com
LifeSci Capital Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Maintains Target Price $44 - moomoo.com
Why Amylyx Pharmaceuticals Blasted Nearly 79% Higher This Week - Yahoo Finance
Amylyx (AMLX) Faces a Binary Phase 3 Test. Can Avexitide Rebuild the Company? - Yahoo Finance
MercadoLibre Stock And 2 High Growth Picks With Strong Balance Sheets - Sahm
Amylyx Pharmaceuticals (AMLX) co-CEO nets 60K performance shares - Stock Titan
Amylyx (NASDAQ: AMLX) CMO’s stock award lifts stake to 288,092 shares - Stock Titan
Amylyx Pharmaceuticals Announces Equity Offering to Fund Avexitide - TipRanks
Amylyx Pharmaceuticals Announces $471.7 Million Public Stock Offering Priced at $35.50 Per Share - Kalkine Media
Amylyx Pharmaceuticals Prices 14.09M-Share Public Offering at $35.50; Nets ~$472M - TradingView
Analysts Conflicted on These Healthcare Names: Amylyx Pharmaceuticals Inc (AMLX), Moderna (MRNA) and Merck & Company (MRK) - The Globe and Mail
Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock - BioSpace
Amylyx Pharmaceuticals Jumps to Fresh Three-Year High as Avexitide Phase 3 Results Bolster Commercial Path - Vinanet
HC Wainwright Has Strong Forecast for AMLX FY2028 Earnings - MarketBeat
39,241 Shares in Amylyx Pharmaceuticals, Inc. $AMLX Bought by GSA Capital Partners LLP - MarketBeat
Amylyx Pharmaceuticals (AMLX) CLO gets 21,284 shares in PSU vesting - Stock Titan
Amylyx prices $500M stock offering at $35.50 per share - Investing.com
Amylyx prices $500M stock offering at $35.50 per share By Investing.com - Investing.com India
Amylyx Pharmaceuticals Announces Pricing Of Upsized $500 Million Underwritten Public Offering Of Common Stock - TradingView
Guggenheim raises Amylyx stock price target on trial results By Investing.com - Investing.com Australia
Amylyx (AMLX) Q2 2026 Earnings Call Transcript - AOL.com
AMLX Rises as Avexitide Nears 2026-End Filing With Phase III Study Win - The Globe and Mail
AMYLYX PHARMACEUTICALS, INC. : LEERINK PARTNERS RAISES TARGET PRICE TO $40 FROM $28 - Bitget
0.18%
0.69%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):